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Abstract
Rationale: Up to one-third of patients hospitalized with
pneumococcal pneumonia experience major adverse cardiac events
(MACE) during or after pneumonia. In mice, Streptococcus
pneumoniae can invade themyocardium, inducecardiomyocytedeath,
and disrupt cardiac function following bacteremia, but it is unknown
whether the same occurs in humans with severe pneumonia.
Objectives:We sought to determine whether S. pneumoniae can (1)
translocate the heart, (2) induce cardiomyocyte death, (3) cause MACE,
and (4) induce cardiac scar formation after antibiotic treatment
during severe pneumonia using a nonhuman primate (NHP) model.
Methods:We examined cardiac tissue from six adult NHPs with
severe pneumococcal pneumonia and three uninfected control
animals. Three animals were rescued with antibiotics (convalescent
animals). Electrocardiographic, echocardiographic, and serum
biomarkers of cardiac damage were measured (troponin T,
N-terminal pro-brain natriuretic peptide, and heart-type fatty acid
binding protein). Histological examination included hematoxylin
and eosin staining, immunoﬂuorescence, immunohistochemistry,
picrosirius red staining, and transmission electron microscopy.
Immunoblots were used to assess the underlying mechanisms.
Measurements and Main Results: Nonspeciﬁc ischemic
alterations were detected by electrocardiography and
echocardiography. Serum levels of troponin T and heart-type fatty
acid binding protein were increased (P, 0.05) after pneumococcal
infection in both acutely ill and convalescent NHPs. S. pneumoniae
was detected in the myocardium of all NHPs with acute severe
pneumonia. Necroptosis and apoptosis were detected in the
myocardium of both acutely ill and convalescent NHPs. Evidence
of cardiac scar formation was observed only in convalescent animals
by transmission electron microscopy and picrosirius red staining.
Conclusions: S. pneumoniae invades the myocardium and induces
cardiac injury with necroptosis and apoptosis, followed by cardiac
scarring after antibiotic therapy, in anNHPmodel of severe pneumonia.
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Lower respiratory tract infections cost the
healthcare system more than $10 billion
annually in the United States (1, 2).
Community-acquired pneumonia (CAP)
and inﬂuenza infections together represent
the fourth most prevalent cause of death
worldwide (3). The morbidity, mortality,
and costs associated with CAP have
remained unchanged in recent decades,
despite the availability of antibiotic
treatments and preventive strategies
with immunizations (4, 5). Approximately
30% of patients hospitalized with CAP
experience major adverse cardiac events
(MACE) during hospitalization and up to
10 years after infection (6–9). Importantly,
patients with pneumonia and MACE
have double the hospital mortality
compared with those with pneumonia
alone (6, 10). MACE in patients with
CAP include new-onset or worsening
heart failure, arrhythmias, stroke, and
acute coronary syndrome (9). Risk factors
for MACE during CAP include infection
with Streptococcus pneumoniae, older age,
severe CAP, hyperlipidemia, obesity,
and arterial hypertension (6, 8, 11, 12).
The pathophysiology of MACE during
CAP has been attributed to the
complex host–pathogen interactions,
but the exact mechanisms are not
well understood (9, 13).
S. pneumoniae (pneumococcus) is
the most frequent bacterial pathogen in
patients with CAP (14, 15). Pneumococcal
pneumonia has been identiﬁed as
an independent risk factor for the
development of MACE during CAP
(6, 8, 11, 12, 16). Pneumococcal pneumonia
can result in cardiovascular complications
in 10 to 30% of patients, affecting mainly
those with existing cardiovascular diseases
(11, 12). Recently, our research group
(17, 18) and other researchers (19–21)
have described that the pneumococcus and
its virulence factors (e.g., pneumolysin,
bacterial cell wall) have direct detrimental
effects on the cardiac function of rodents
with invasive pneumococcal disease
(IPD). We have demonstrated that
pneumococcus can invade the heart and
cause small, bacteria-ﬁlled lesions
within the myocardium (17, 18). These
myocardial lesions disrupt cardiac
contractility, induce cardiomyocyte death,
and subsequently cause de novo collagen
deposition in mice rescued with antibiotics
(convalescent mice) (17, 22). Moreover,
we have shown that S. pneumoniae is
capable of inducing necroptosis, a
highly proinﬂammatory programmed
cell death pathway, in lung macrophages
during pneumonia (23). Pertinent to the
present study, necroptosis has been
recognized as a key cell death pathway
in cardiomyocytes during ischemia-
reperfusion injury and acute coronary
syndrome (24–26).
Despite epidemiological studies
demonstrating that pneumococcal infection
is an independent risk factor for MACE
(6–8, 11, 12), it is unknown whether
S. pneumoniae can generate direct cardiac
cytotoxicity (e.g., cell death), heart failure,
clinically relevant arrhythmias, or acute
coronary syndrome (i.e., MACE) in
humans with severe pneumococcal
pneumonia (11, 12, 16, 27). Additionally,
the potential underlying mechanisms of
MACE during pneumococcal pneumonia
have been described in rodent models, but
it is speculative to extrapolate these ﬁndings
to humans. To address this knowledge gap,
we used a validated nonhuman primate
(NHP) model of severe pneumococcal
pneumonia that closely mimics human
disease (28) to explore the mechanisms
of pneumococcal cytotoxicity on
cardiomyocytes. Potential translation of
these ﬁndings to humans includes
identiﬁcation of potential therapeutic
targets to prevent MACE and, ultimately,
improvement in clinical outcomes
of patients with CAP.
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At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: Streptococcus pneumoniae is
the most frequently isolated bacterial
pathogen in patients with community-
acquired pneumonia (CAP). As a
result of highly complex
host–pathogen interactions, patients
with pneumococcal pneumonia are at
increased risk of developing
cardiovascular complications during
and after CAP, including heart failure,
arrhythmias, stroke, and acute
coronary syndrome. Recent studies in
mice revealed that S. pneumoniae is
capable of invading the heart and
causing direct cardiac damage during
invasive pneumococcal disease. Yet,
murine pneumococcal pneumonia is
poorly representative of human
disease, and whether cardiac invasion
occurs during severe pneumonia in
humans is unknown. Our aim in this
study was to determine, using a
validated nonhuman primate model
that closely resembles pneumococcal
disease in humans, if pneumococcus
(1) invades the myocardium, (2)
induces cardiomyocyte death, and (3)
elicits cardiovascular complications
during pneumococcal pneumonia.
What This Study Adds to the
Field: This study presents novel
evidence that S. pneumoniae can
invade the heart during severe
pneumonia and induce cardiomyocyte
death via direct cytotoxic effects.
These ﬁndings could potentially
explain the development of short- and
long-term cardiac complications
associated with CAP due to acute
cardiomyocyte injury and induction of
scar formation in the hearts of
convalescent nonhuman primates.
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Methods
These animal studies were performed at the
Texas Biomedical Research Institute in
San Antonio, Texas. This animal protocol
along with all animal experiments were
reviewed and approved by the institutional
animal care and use committee (IACUC
number 1443PC6) at the Texas Biomedical
Research Institute.
Study Design
A full description of the NHP model of
severe pneumococcal pneumonia has
been published previously (28). Brieﬂy,
six healthy adult baboons (Papio
cynocephalus), including four males, were
bronchoscopically challenged with 109
colony-forming units of S. pneumoniae
serotype 4 (strain TIGR4 [29]). Collection
of blood for serum biomarkers and
bacterial load estimation, acquisition of a
12-lead ECG and a transthoracic
echocardiogram, and bronchoalveolar
lavage were performed before the infection
and at the end of the experiment before
animals were killed (28). Continuous 24-
hour temperature, heart rate, and three-lead
ECG were recorded throughout the
experiment via a surgically implanted tether.
At the end of the experiment, the hearts
were harvested and prepared for tissue
experiments. Three NHPs were treated with
intravenous ampicillin (80 mg/kg/d) for 7
days (the convalescent group) (28). All ECGs
were read by an expert electrophysiologist
(A.J.) who was blinded to the experiment
results. The study design is summarized in
Figure E1 in the online supplement. Finally,
MACE were deﬁned as heart failure,
arrhythmias, or myocardial infarctions.
Study Groups
The cohort was divided in two groups to
mimic the preantibiotic era and modern era
of patients with pneumonia (28). For the
preantibiotic era group, we did not treat
three NHPs with antibiotics, and they
were called the acute pneumonia group
and killed per protocol 4–6 days after
infection. In the modern era of pneumonia
group, three NHPs were rescued with
antibiotic treatment, and they were called
the convalescent pneumonia group and
killed per protocol 9–14 days after
infection (28). The end of the experiment
refers to the moment before animals were
killed, which varied for each animal
according to the study groups just
described (28). Heart tissues of three
age- and sex-matched uninfected NHPs
served as controls (Figure E1).
Transthoracic Echocardiogram
Evaluation
A standard ﬁve-view focused cardiac
ultrasound examination was performed
using a portable ultrasound machine (GE
LOGIQ e Vet; GE Healthcare, Little
Chalfont, UK) equipped with microconvex
(GE model 8C-RS, 4.0–10.0 MHz; GE
Healthcare) and phased-array (GE model 3S-
RS, 1.7–4.0 MHz; GE Healthcare) transducers.
Parasternal long- and short-axis, apical and
subcostal four-chamber, and subcostal inferior
vena cava (IVC) views were obtained to assess
the left ventricular (LV) and right ventricular
size and function, cardiac valves, pericardium,
and IVC size and collapsibility.
Serum Cardiac Biomarkers
Serum levels of ultrasensitive troponin T (Life
Diagnostics, West Chester, PA), heart-type
fatty acid binding protein (H-FABP; Kamiya
Biomedical, Seattle,WA), andN-terminal pro-
brain natriuretic peptide (Neo Scientiﬁc,
Cambridge, MA) were measured by ELISA in
serum samples before infection and at the end
of the experiment. Cytokine and chemokine
analyses were performed using a validated
Luminex multiplex assay for NHPs (30).
Tissue Staining and Microscopy
Immunoﬂuorescent and
immunohistochemical (IHC) staining was
performed with parafﬁn-embedded tissues
as previously described (18). Primary
antibodies used in this study included those
against serotype 4 capsular polysaccharide
antibody (Statens Serum Institut,
Copenhagen, Denmark); pneumolysin
(Santa Cruz Biotechnology, Dallas, TX),
transforming growth factor (TGF)-b (Bio-
Rad Laboratories, Hercules, CA), pSMAD3,
mixed lineage kinase domain-like
pseudokinase (MLKL), phosphorylated
MLKL (pMLKL), caspase 3 (Cell Signaling
Technology, Danvers, MA), receptor-
interacting protein kinase 3 (RIP3; Abcam,
Cambridge, UK), and hypoxia-inducible
factor (HIF)-1a (Bethyl Laboratories,
Montgomery, TX). The secondary antibody
used was ﬂuorescein isothiocyanate–
labeled goat antirabbit antibody (Jackson
ImmunoResearch, West Grove, PA).
Picrosirius red–stained (Electron Microscopy
Sciences, Hatﬁeld, PA) and hematoxylin and
eosin–stained heart sections were scanned
with an Aperio ScanScope XT scanner
(Aperio Technologies, Leica Biosystems,
Wetzlar, Germany). Immunoﬂuorescent
and IHC images were captured with an
Olympus AX70 microscope (Olympus
America, Center Valley, PA). Transmission
electron microscopy (TEM) was performed
with a JEOL JEM 1230 transmission electron
microscope (JEOL, Peabody, MA).
Immunoblotting
Hearts were homogenized and processed as
previously described (23) with protease
(Sigma-Aldrich, St. Louis, MO) and
phosphatase (Thermo Fisher Scientiﬁc,
Waltham, MA) inhibitors.
Statistical Analysis
All data are presented as median with
interquartile range (IQR) or mean with SD
as appropriate. Paired nonparametric
Wilcoxon signed-rank tests or two-tailed
Student’s t tests were used to compare data
at different time points. All statistical
Table 1. Twelve-Lead ECG Quantitative Analysis of All Six Nonhuman Primates
Variable Baseline End of Experiment P Value
Heart rate, beats/min 78 (69–99.5) 122 (102.5–152) 0.001
P-wave duration, ms 80 (76.5–87.5) 80 (70–100) 0.728
PR interval, ms 140 (121.5–155) 135 (125–155) 0.893
RR interval, ms 769.23 (603.15–869.74) 491.93 (394.73–586.36) 0.001
QRS interval, ms 55 (47.5–62.5) 55 (50–63.75) 0.874
QT interval, ms 310 (287.5–347.5) 292.50 (281.25–317.5) 0.323
Corrected QT interval, ms 369.76 (341.53–398.36) 440.20 (398.29–454.36) 0.001
ST segment, ms 125 (100–160) 114 (91.25–132.5) 0.308
T-wave duration, ms 125 (120–140) 130 (125–143.75) 0.229
Data are presented as median with interquartile range, and statistically significant P values are
presented in bold.
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calculations were performed using Prism 5
software (GraphPad Software, La Jolla, CA).
Two-tailed P values less than 0.05 were
considered statistically signiﬁcant.
Results
Six NHPs with a median age of 11 (IQR,
10–19) years, which corresponds to
middle-aged to elderly in humans, were
included in the study. Details about each
NHP, as well as an overview of the
experiments done to develop the severe
pneumococcal pneumonia model, were
previously described (28). Demographics and
pneumonia severity are presented in Table E1.
Noninvasive Cardiac Evaluation
ECG evaluation. During baseline
evaluation, all animals were in sinus rhythm
with normal PR, QT, and ST intervals
(Table 1, Figure 1A). P, T, and QRS waves
resembled their normal morphology in
humans (Figure 1A). At the end of the
experiment, immediately before the animals
were killed, ECG evaluation showed that all six
NHPs had developed sinus tachycardia, diffuse
repolarization abnormalities represented by
diffuse ST segment changes, T-wave ﬂattening,
and prolongation of the corrected QT
interval (Figures 1B–1E, Table 1). Table 2
presents the individual interpretations of the
12-lead ECGs at baseline and at the end of the
experiment. No other signiﬁcant alterations
were detected in the ECG tracings, even after
the cohort was stratiﬁed by acute or
convalescent pneumonia (Table E2).
Echocardiographic ﬁndings. A qualitative
focused cardiac ultrasound examination was
conducted at baseline and at the end of the
experiment. Findings are summarized in
Table E3. Prior to infection, all six NHPs
had normal focused cardiac ultrasound
examinations. NHPs with acute pneumonia
demonstrated hyperdynamic LV function,
moderate tricuspid regurgitation, small
pericardial effusions, and collapsed IVCs
(central venous pressure ,5 mm Hg). NHPs
with convalescent pneumonia developed
increased LV relative wall thickness and some
associated wall motion abnormalities
(hypokinesis).
Serum biomarkers. Troponin T and
H-FABP serum levels were elevated at the
end of the experiment in all NHPs compared
with baseline levels (median [IQR], 0.005
ng/ml [0.000–0.025] vs. 0.044 ng/ml
A
B
C
D
E
Figure 1. Nonhuman primates with severe pneumococcal pneumonia developed diffuse, nonspecific
repolarization abnormalities. Twelve-lead ECGs were recorded (A) at baseline and (B–E) at the end of
the experiment. (A) At baseline, all animals were in sinus rhythm with no repolarization abnormalities.
After development of pneumococcal pneumonia, the ECGs consistently showed (B and C) sinus
tachycardia and (B–E) abnormal repolarization (i.e., diffuse T-wave and ST-segment flattening).
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[0.036–0.057]; P = 0.002; and 150.8 ng/ml
[33.25–281.5] vs. 916.9 ng/ml
[595.8–1,323]; P = 0.002, respectively)
(Figures 2A and 2C). When we stratiﬁed
the cohort by acute or convalescent
pneumonia (i.e., with vs. without antibiotic
treatment), troponin T and H-FABP
remained higher at the end of the
experiment in both cohorts, but the
troponin T concentration was not
statistically signiﬁcant higher than it was at
baseline (Figures 2B and 2D). In contrast,
Table 2. Qualitative Individual Interpretation of 12-Lead ECGs at Baseline and End of the Experiment
Animal
Electrocardiographic Findings
Baseline End of Experiment
Acute pneumonia 1 Biphasic T waves in lateral leads Inverted T waves in inferior and anterolateral leads
2 No repolarization abnormalities Slow ventricular rhythm
3 Diffuse ST-segment and T-wave ﬂattening Q waves on lateral leads, ST-segment and T-wave
ﬂattening in inferolateral leads
Convalescent pneumonia 4 No repolarization abnormalities Diffuse ST-segment and T-wave ﬂattening
5 Short QT segment Diffuse ST-segment and T-wave ﬂattening
6 No repolarization abnormalities Q waves in lateral leads, T-wave inversion in lateral
leads, and ST-segment depression in inferior leads
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Figure 2. Serum concentrations of cardiac damage biomarkers were elevated in animals with acute and convalescent pneumococcal pneumonia. The
serum biomarkers of cardiac damage, troponin T, heart-type fatty acid binding protein (H-FABP), and N-terminal pro-brain natriuretic peptide (NT-proBNP)
were assessed before infection, at Days 4–6 for the acute group, and at Days 9–14 for the convalescent group. Median (n = 6) serum concentrations
of (A) troponin T, (C) H-FABP, and (E) NT-proBNP are shown before infection and at the end of the experiment (i.e., before animals were killed). To
test whether antibiotic treatment could prevent cardiac damage, the cohort was stratified into nonhuman primates with acute pneumonia (i.e., without
antibiotics; n = 6) and nonhuman primates with convalescent pneumonia (i.e., with antibiotics; n = 3). Serum levels of (B) troponin T, (D) H-FABP, and
(F) NT-proBNP were assessed for each group before infection, at Days 4–6 for the acute group, and at Days 9–14 for the convalescent group. Values
are shown as medians with interquartile ranges. A paired nonparametric Wilcoxon signed-rank test was used to analyze statistical differences among
the groups. *P, 0.05; **P, 0.01. ns = not significant.
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serum N-terminal pro-brain natriuretic
peptide serum levels did not change
signiﬁcantly at the end of the experiment
(194.2 pg/ml [22.21–815.1] vs. 141.9 pg/ml
[39.8–565.5]; P = 0.9) (Figures 2E and 2F).
Invasive Cardiac Evaluation
Detection of S. pneumoniae. We performed
immunoﬂuorescent staining of the different
parts of the heart in all animals and
conﬁrmed the invasion of S. pneumoniae in
the myocardium (Figure 3A and 3B). In
NHPs with acute pneumonia, we observed
clusters of pneumococci, suggesting that the
bacteria were capable of replicating
within the tissue. In contrast, in NHPs
with convalescent pneumonia, only a
few punctate points were observed,
representing S. pneumoniae capsule debris
(Figure 3C). Quantiﬁcation of bacteria
in heart homogenates conﬁrmed that
S. pneumoniae was present in NHPs with
acute pneumonia, and none was detected in
those with convalescent pneumonia or in
uninfected control animals (Figure E2).
Histopathological ﬁndings. Tissue
sections of the right or left ventricle and the
interventricular septum showed similar
lesions of a focal cardiac injury, primarily in
perivascular sites, of varying extent and
severity determined by hematoxylin and
eosin staining (Figure E3). Affected cardiac
myocytes were enlarged, with a striking
increase in eosinophilic staining, and were
well demarcated from adjacent cardiac
tissue (Figures 4A–4C). The damage of left
ventricles and septum varied in terms of
size and inﬁltration (Figure E3). Varying
degenerative and/or necrotic lesions were
observed in the left ventricle and
interventricular septum (Figures 4A–4C).
All animals had mild to severe myocyte
fatty change and vacuolization, focal
contraction bands, interstitial edema, focal
myocytolysis, and scattered inﬂammatory
cells (Figures 4A and 4B). We observed
scattered myocytolysis in several myocytes
(Figures 4A and 4B), but prominent nuclear
pyknosis with extensive myocytolysis was
apparent in several myocytes (Figure 4C).
Two NHPs exhibited additional necrotic
lesions deﬁned by nuclear karyolysis and
fragmentation, although one site had some
clumped bacteria (Figure 4C).
Using TEM, we observed that infected
NHPs consistently developed areas of
vacuolization with focal contraction bands
and interstitial edema in the left ventricle
and septum (Figures 4E and 4F).
Additionally, we identiﬁed several areas
with focal myocytolysis and nuclear
pyknosis that corresponded to extensive
mitochondrial damage characterized by
swollen and electron-lucent matrices
(Figure 4G). Moreover, the mitochondrial
cristae were degraded and disorganized and
had decreased density. All these changes
were evident in both the acute and
convalescent pneumonia groups (Figures
4E–4G).
Cardiac inﬂammatory response. We
observed high concentrations of cytokines
and chemokines, including IL-6, tumor
necrosis factor (TNF)-a, IL-8, IL-1b,
IL-1Ra, and macrophage inﬂammatory
protein 1a in homogenized hearts (left
ventricle and interventricular septum) of all
NHPs with acute pneumonia (Figure 5). All
three NHPs with convalescent pneumonia
had lower heart concentrations of cytokines
and chemokines than NHPs with acute
pneumonia (Figures 5A–5F). Signiﬁcantly
higher concentrations of IL-6, TNF-a, and
IL-1b were seen in the left ventricle and
interventricular septum of infected NHPs
versus uninfected control animals (Figures
5B, 5D, and 5E). IL-8 levels were higher in
the interventricular septum (Figure 5C) of
NHPs with convalescent pneumonia than
in uninfected control animals.
Cardiomyocyte death. To test the role
of necroptosis in cardiomyocyte death, we
stained for RIP3 and pMLKL (necroptosis
effector) in heart tissues from infected NHPs
with acute and convalescent pneumonia and
uninfected control animals using IHC
staining (Figure 6A). An increased signal of
both RIP3 and pMLKL was seen in stained
tissues, suggesting that necroptosis was
taking place throughout the myocardium.
Increased levels of both RIP3 and pMLKL
were conﬁrmed by immunoblot analysis
(Figure 6B). Additional staining of cardiac
tissues with CardioTAC (R&D Systems,
Minneapolis, MN) suggested apoptotic cells in
the myocardium (Figure E4). Brieﬂy,
CardioTAC labels DNA ends using terminal
deoxynucleotidyl transferase. In addition,
consistent with the presence of apoptotic cells
in the myocardium, we observed an increase
of apoptosis effector caspase 3 mainly in
NHPs with acute pneumonia (Figure E4).
Collectively, these results suggest that
S. pneumoniae induces programmed death
pathways after it invades the myocardium.
Cardiac ﬁbrosis. TGF-b in the heart
stimulates myoﬁbroblasts to produce
collagen to replace dead cardiomyocytes
(31, 32). After S. pneumoniae had induced
necroptosis in the heart, de novo collagen
deposition was detected in the left ventricle
and septum, as evidenced by picrosirius red
staining (Figure 7A) and TEM (Figure 7B).
Collagen deposition was seen 9–14 days
DAPI Capsule Streptococcus pneumoniae
4
C
/F
P
O
Figure 3. Streptococcus pneumoniae translocates into the heart during pneumonia. Representative
images from (A and C) left ventricular and (B) interventricular septal sections from the six nonhuman
primates (NHPs) with pneumococcal pneumonia and (D) three uninfected control animals.
S. pneumoniae was visualized using immunofluorescent staining with antiserum against serotype 4
capsular polysaccharide (green) and 49,6-diamidino-2-phenylindole (DAPI; blue) to reveal nucleated
tissue cells. (A and B) Bacterial aggregates with diplococci morphology are seen within the left
ventricles and septa of NHPs with acute pneumonia. (A) Bacterial cluster conformation indicates
active replication. (C) Single-capsule debris (marked with the white arrow) were scattered throughout
the left ventricles and in the interventricular septa of convalescent NHPs. (D) Pneumococcal capsules
were not identified in the hearts of uninfected control NHPs.
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after infection in convalescent animals.
Additionally, using immunoblot analysis,
we identiﬁed increased expression of
pSMAD3, which stimulates collagen
production in cardiac myoﬁbroblasts (33).
Finally, to conﬁrm that cardiac injury
and collagen deposition were secondary to
S. pneumoniae invasion, we explored the
HIF-1a pathway that is activated by hypoxia
(34). Immunoblotting in homogenized
hearts of NHPs conﬁrmed that the HIF-1a
pathway was downregulated in both the
acute and convalescent pneumonia groups
(Figure E5).
Discussion
The results of our study provide novel
evidence that, similarly to humans, NHPs
with severe pneumococcal pneumonia
develop signs of cardiac injury, including
diffuse repolarization abnormalities,
hyperdynamic LV function, and
mild elevation of serum biomarkers
(i.e., troponin T and H-FABP). Microscopic
examination of heart tissues revealed that
pneumococcus is capable of translocating
into the myocardium and inducing
cardiomyocytes by necroptosis and
apoptosis. Moreover, we conﬁrmed that
heart invasion by S. pneumoniae
causes severe cardiac injury and local
proinﬂammatory responses independent of
antibiotic treatment. We provide evidence
that NHPs with convalescent pneumonia
develop interstitial collagen deposition
(i.e., scar formation) secondary to TGF-b
pathway activation. Our ﬁndings are
novel in that they provide translational
data highlighting the etiological role of
S. pneumoniae in causing MACE in
patients with pneumonia. Further, collagen
deposition in the myocardium may explain
the increased long-term risk of MACE after
an acute episode of pneumococcal
pneumonia.
Up to 36% of patients hospitalized with
CAP develop severe disease, which requires
admission to the intensive care unit (35, 36).
Owing to the severe inﬂammatory response
and mitochondrial dysfunction during
severe pneumonia, at least 30% of
patients develop LV dilation with a reduced
ejection fraction, which usually takes 7–10
days to recover (i.e., sepsis-induced
cardiomyopathy) (37, 38). In addition,
Corrales-Medina and colleagues showed
recently in a cohort study that 10 to 30%
of adults (without a clinical history of
cardiac disease) admitted for CAP
developed clinically relevant heart failure,
arrhythmias, or acute coronary syndrome
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Figure 4. Hearts of nonhuman primates (NHPs) with severe pneumonia developed severe cardiac injury with variable pathological characteristics.
Representative hematoxylin and eosin–stained and transmission electron microscopic images of heart specimens from (A, B, and E) NHPs with acute
pneumococcal pneumonia and (C, F, and G) NHPs with convalescent pneumonia, as well as (D and H) uninfected control NHPs. (A and G) NHPs
developed myocyte cytoplasm degenerative changes, including fatty change, vacuolization, and myofibrillar separation. (A and E) Perinuclear and
interstitial edema are evident, and several myocyte nuclei contain condensed chromatin, a necrotic change. (B and F) Additionally, in the left ventricle,
myocytes with cytoplasmic changes of contraction bands, focal vacuolization, and myocytolysis were identified. (B) The edematous interstitium contained
increased small mononuclear cells and some neutrophils. (B and G) Nuclear edema and karyolysis are diffusely evident in cardiomyocytes. (C, E, and F)
Widespread myocytolysis, contraction bands, striking nuclear pyknosis, and karyolysis are seen in the septum. (F and G) Finally, degradation of
mitochondrial cristae and edema were consistently observed by transmission electron microscopy.
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up to 10 years after hospitalization (6–8).
More commonly, up to 59% of patients
admitted with sepsis develop a cardiac
phenomenon called demand ischemia
(i.e., mild troponin elevation and
repolarization abnormalities in the absence
of myocardial infarction or coronary
disease) rather than sepsis-induced
cardiomyopathy or MACE (39–41). In our
study, we found that all six previously
healthy NHPs with pneumococcal
pneumonia developed nonspeciﬁc cardiac
changes that cannot be categorized as
MACE but are consistent with what
clinicians call demand ischemia. In contrast
to human studies, in our present study,
we were able to perform a detailed ex vivo
examination of the NHP hearts, which
revealed that S. pneumoniae can invade the
heart and induce severe cardiac injury by
killing cardiomyocytes through necroptosis
and apoptosis.
S. pneumoniae and its virulence factors
(e.g., pneumolysin, cell wall) are cytotoxic
and capable of inducing inﬂammation in
cardiomyocytes (17, 19, 20). Recently, our
research group described the novel
observation that the pneumococcus is
capable of invading the myocardium and
forming nonpurulent, bacteria-ﬁlled,
microscopic lesions that were associated
with cardiomyocyte death (apoptosis) and
electrocardiographic abnormalities in mice
with IPD (22). In our experiments with
severe pneumococcal pneumonia in NHPs,
we proved that the pneumococcus is
capable of invading the bloodstream and
translocating the myocardium. In the hearts
of NHPs, S. pneumoniae was observed in
clusters, representing active replication,
which did not form microlesions as
previously described in mice (18). This
difference may be explained by the high
bacterial load and longer infection times
required to develop mature microlesions.
Gilley and colleagues (18) recently
described how cardiac invasion by
pneumococcus occurs as soon as 12 hours
after infection, but microlesion formation
was dependent on bacterial load and time.
Although similar ﬁndings have been
reported in an IPD model that is not
representative of pneumococcal pneumonia
in humans, we used an NHP model of
severe pneumonia that closely mimics the
development and pathogenesis of human
disease in that all the animals develop low-
grade bacteremia for a short period (28).
Cardiomyocytes have been shown to
die by apoptosis or necroptosis during
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Figure 5. Cytokines and chemokines present in homogenized hearts of nonhuman primates (NHPs) with acute or convalescent pneumococcal
pneumonia. Median concentrations of proinflammatory cytokines in homogenized left ventricles and interventricular septa of NHPs with acute and
convalescent pneumococcal pneumonia are shown. NHPs with acute pneumonia had higher concentrations of (A) IL-6, (B) tumor necrosis factor (TNF)-⍺,
(C) IL-8, (D) IL-1b, (E) IL-1R⍺, and (F) macrophage inflammatory protein (MIP)-1⍺ than uninfected NHPs. Convalescent NHPs had lower concentrations of
cytokines than NHPs with acute pneumonia, but (A) IL-6, (B) TNF-⍺, (C) IL-8, and (D) IL-1b persisted at higher levels than in uninfected control animals.
Values are shown as medians and interquartile ranges. An unpaired nonparametric Mann-Whitney U test was used to analyze statistical differences
among the groups. All comparisons were made against uninfected control animals. *P, 0.05; **P, 0.01; ***P, 0.001. ns = not significant.
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injury or disease (24–26). Apoptosis is an
immunoquiescent form of cell death that
requires the activity of cysteine proteases
known as caspases (42). It has been shown
that mice lacking the death receptor Fas or
mice treated with chemical inhibitors of
caspases have reduced heart infarct sizes
and fewer apoptosis-positive cells after
ischemia-reperfusion injuries (43). In
contrast to apoptosis, necroptosis, or
programmed necrosis, causes severe
inﬂammation and tissue damage during
disease (44). Necroptosis is modulated by
activation of RIP1, RIP3, and the effector
molecule MLKL (25, 45). Recently, Yin and
colleagues showed that a nonspeciﬁc
inhibitor of RIP1, necrostatin-1, could
reduce infarct sizes after major ischemia or
reperfusion injuries (46). Using an NHP
model, we showed that cardiomyocytes
undergo RIP1-RIP3-MLKL–dependent
necroptosis, and necroptosis inhibition
with a selective drug has been shown to be
protective against S. pneumoniae–induced
cardiac damage, as reported by Gonzalez-
Juarbe and colleagues (47). This ﬁnding is
signiﬁcant because killing cardiomyocytes
and inducing a proinﬂammatory response
may contribute to the generation of MACE
during pneumococcal pneumonia.
Antibiotics have been shown to
drastically reduce mortality resulting from
pneumonia and other infectious diseases,
and they are the cornerstone of CAP
treatment (5). Thus, to mimic the disease
evolution of CAP in humans, we treated
NHPs with ampicillin to explore whether
antibiotic treatment could prevent the
development of cardiac injury secondary to
S. pneumoniae invasion. We found that
antibiotic treatment did not protect NHPs
from the development of necroptosis or
cardiac injury and, more important, that
NHPs treated with antibiotics had scar
formation in the heart. These ﬁndings are
consistent with our ﬁndings in mice
rescued from IPD with antibiotics (17)
and of other experiments in mice with
ischemia-reperfusion injury (31). This
ﬁnding improves our understanding of
MACE and the long-term mortality of
patients with CAP. As described by Souders
and colleagues, once cardiomyocytes die,
heart tissue is replaced with myoﬁbroblasts
that produce an extracellular matrix
that is rich in collagen and leads to scar
formation (48). Because S. pneumoniae is
capable of inducing cardiac scar formation,
and because cardiac scars are known to cause
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Figure 6. Necroptosis in heart tissue increases after antibiotic treatment. Immunohistochemistry was
used to elucidate the cell pathways involved during cell death in nonhuman primates (NHPs) with
pneumococcal pneumonia. Immunohistochemistry of heart sections stained for (A) receptor-interacting
protein kinase 3 (RIP3) and (B) phosphorylated mixed lineage kinase domain-like pseudokinase (pMLKL).
(C) Immunoblot analysis for RIP3, pMLKL, and succinate dehydrogenase complex, subunit A (SDHA;
loading control), in heart tissue of infected NHPs versus uninfected control animals. (D) Relative levels of
RIP3 and pMLKL protein expression determined by comparing the ratio of the detected band with total
protein levels as determined using LI-COR Image Studio Lite software (LI-COR Biosciences, Lincoln, NE).
Values are shown as medians and interquartile ranges. Unpaired nonparametric Mann-Whitney U
tests were used to analyze statistical differences among the groups. *P, 0.05. ns = not significant.
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arrhythmias and heart failure, our ﬁndings
might explain why MACE occur up to
10 years after the acute infection.
MACE are the result of a complex
host–pathogen interaction between
underlying comorbidities, the infectious
pathogen (9), systemic inﬂammation (49),
endothelial dysfunction (50), a relative
prothrombotic state (9), increased cardiac
oxygen demand, and low blood oxygen
levels, which places considerable stress on
the heart (9). In this study, we show that
pathogen-speciﬁc mechanisms of
S. pneumoniae contribute to the
development of cardiac damage during
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Figure 7. Streptococcus pneumoniae induces de novo collagen deposition in nonhuman primates (NHPs) with convalescent pneumonia. Representative
images of heart sections from the six NHPs infected with S. pneumoniae and three uninfected control animals. (A) Picrosirius red was used to identify
collagen deposition. NHPs with convalescent pneumonia developed collagen deposition throughout the left ventricle and interventricular septum. (B)
Transmission electron microscopy (TEM) was used to confirm collagen deposition, identifying areas with conglomerates of collagen fibers in NHPs that
survived their acute pneumonia. (C) The upregulation of pSMAD3 in convalescent NHPs was identified by immunoblot analysis, and (D) relative protein
levels (pSMAD3/succinate dehydrogenase complex, subunit A [SDHA; loading control]) were determined using LI-COR Image Studio Lite software.
Values are shown as medians and interquartile ranges. Unpaired nonparametric Mann-Whitney U tests were used to analyze statistical differences
among the groups. *P, 0.05; **P, 0.01; ns = not significant.
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pneumococcal pneumonia that could lead
to MACE.
Our study has some important
limitations. First, the experimental design
was limited to a 2-week maximum duration,
and the ﬁndings should not be interpreted as
long-term clinical outcomes after surviving
CAP. Second, the clinical evaluation was
limited in capabilities to continuously assess
oxygenation or hemodynamic parameters
that could be associated with cardiac injury.
However, at the end of the experiments, the
NHPs were not hypotensive to a level
requiring vasopressor support. Third, we
did not speciﬁcally examine coronary
arteries to identify thrombi or signs of
myocardial infarction. However, we ruled
out the clinical diagnosis of myocardial
infarction according to the current
guidelines of the American Heart
Association (51). Finally, the sample
size was limited to six NHPs with
pneumococcal pneumonia owing to
ethical considerations and high costs
associated with the implantable continuous
noninvasive cardiovascular monitoring
systems and intensive veterinary
medical care.
In summary, severe pneumococcal
pneumonia led to the development of
cardiac injury due to direct pathogen
invasion, induction of cell death
(necroptosis and apoptosis), and subsequent
cardiac scar formation after antibiotic
treatment in an NHP model. Further
research is needed to develop strategies to
mitigate the pathological mechanisms
underlying cardiac injury secondary to
pneumococcal invasion. n
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